By otakuyassine3@gmail.com 
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 3,260,000 shares, a drop of 18.9% from the November 30th total of 4,020,000 shares. Based on an average trading volume of 311,200 shares, the short-interest ratio is currently 10.5 days.
Insider Activity
In related news, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the sale, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. The trade was a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,092 shares of company stock valued at $673,039. Insiders own 54.57% of the company’s stock.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $4,997,000. Franklin Resources Inc. grew its position in Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after purchasing an additional 1,100 shares in the last quarter. XTX Topco Ltd increased its stake in Kiniksa Pharmaceuticals by 62.2% in the 3rd quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock valued at $682,000 after buying an additional 10,474 shares during the last quarter. Castleark Management LLC bought a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $4,178,000. Finally, Jane Street Group LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 1,064.4% in the 3rd quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after buying an additional 315,456 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.
Kiniksa Pharmaceuticals Stock Performance
Kiniksa Pharmaceuticals stock traded down $0.10 during mid-day trading on Friday, reaching $20.01. The stock had a trading volume of 394,362 shares, compared to its average volume of 397,435. The firm has a market capitalization of $1.44 billion, a PE ratio of -142.92 and a beta of 0.27. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15. The stock’s 50-day simple moving average is $22.13 and its 200-day simple moving average is $23.15.
Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same period in the previous year, the business posted ($0.20) EPS. The business’s revenue for the quarter was up 67.4% compared to the same quarter last year. On average, research analysts forecast that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently weighed in on KNSA shares. JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Evercore ISI boosted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $36.60.
View Our Latest Stock Analysis on Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Further Reading
Receive News & Ratings for Kiniksa Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.